COVID-19: impact on blood and transfusion services

Detalhes bibliográficos
Autor(a) principal: Leitão, Céu
Data de Publicação: 2022
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25758/set.2265
Resumo: A novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy.
id RCAP_268030f9f713b30aaacad24f8862ea9e
oai_identifier_str oai:journals.ipl.pt:article/570
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling COVID-19: impact on blood and transfusion servicesCOVID-19: impacto nos serviços de sangue e de medicina transfusionalCOVID-19Medicina transfusionalPlasma convalescenteServiços de sangueCOVID-19Transfusion medicineConvalescent plasmaBlood bankA novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy.Assiste-se à emergência de um novo coronavírus com um ciclo de infeção exponencial e universal e elevadas taxas de morbilidade e mortalidade. Designado como SARS-CoV-2 e dada a sintomatologia dos doentes com défice respiratório severo e pneumonia grave, o novo vírus obrigou à declaração de pandemia, forçando medidas de confinamento das populações. A doença originada pela infeção designada por Coronavirus disease 2019 (COVID-19) resultou em todos os países numa drástica diminuição do número de dadores de sangue disponíveis, por estarem infetados ou em confinamento ou ainda devido ao aumento da taxa de reprovação para prevenir o risco da dádiva de sangue por indivíduos com infeção, mas assintomáticos. O Instituto Português do Sangue e da Transplantação, em parceria com os outros organismos nacionais responsáveis, de imediato formulou um plano de contingência com caráter normativo de forma a garantir e manter um suporte terapêutico seguro de componentes sanguíneos em todas as solicitações hospitalares. Independentemente das políticas de segurança aplicadas de forma sistemática no processo transfusional, como a realização dos testes de ácidos nucleicos em todas as dádivas, a desleucocitação e a inativação patogénica dos componentes sanguíneos, até que haja mais conhecimento sobre a epidemiologia e patogenicidade do SARS-CoV-2 impõe-se no setor da medicina transfusional o princípio da precaução, lição aprendida desde há anos face aos surtos anteriores. Neste momento, os laboratórios de referência dos Centros de Sangue e da Transplantação, Área Funcional do Sangue, trabalham intensamente na identificação e rastreio dos potenciais dadores de plasma convalescente COVID-19 como opção terapêutica, tendo em conta a ausência atual de vacinas ou medicação específica.Escola Superior de Tecnologia da Saúde de Lisboa (Instituto Politécnico de Lisboa)2022-08-24info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25758/set.2265oai:journals.ipl.pt:article/570Saúde e Tecnologia; No. T3 (2020): Nº temático - COVID-19; e22-e28Saúde & Tecnologia; N.º T3 (2020): Nº temático - COVID-19; e22-e281646-9704reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://journals.ipl.pt/stecnologia/article/view/570https://doi.org/10.25758/set.2265https://journals.ipl.pt/stecnologia/article/view/570/497Direitos de Autor (c) 2022 Saúde & Tecnologiainfo:eu-repo/semantics/openAccessLeitão, Céu2022-12-20T10:58:56Zoai:journals.ipl.pt:article/570Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:21:23.425870Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv COVID-19: impact on blood and transfusion services
COVID-19: impacto nos serviços de sangue e de medicina transfusional
title COVID-19: impact on blood and transfusion services
spellingShingle COVID-19: impact on blood and transfusion services
Leitão, Céu
COVID-19
Medicina transfusional
Plasma convalescente
Serviços de sangue
COVID-19
Transfusion medicine
Convalescent plasma
Blood bank
title_short COVID-19: impact on blood and transfusion services
title_full COVID-19: impact on blood and transfusion services
title_fullStr COVID-19: impact on blood and transfusion services
title_full_unstemmed COVID-19: impact on blood and transfusion services
title_sort COVID-19: impact on blood and transfusion services
author Leitão, Céu
author_facet Leitão, Céu
author_role author
dc.contributor.author.fl_str_mv Leitão, Céu
dc.subject.por.fl_str_mv COVID-19
Medicina transfusional
Plasma convalescente
Serviços de sangue
COVID-19
Transfusion medicine
Convalescent plasma
Blood bank
topic COVID-19
Medicina transfusional
Plasma convalescente
Serviços de sangue
COVID-19
Transfusion medicine
Convalescent plasma
Blood bank
description A novel coronavirus emerged with an exponential and universal cycle of infection, carrying great morbidity and mortality rate. Since the patients suffer from the severe acute respiratory syndrome, the new virus designated as SARS-CoV-2, caused an outbreak and the pronouncement of a pandemic state, forcing people into isolation. The disease named Coronavirus disease 2019 (COVID-19) led to a drastic decline in blood supply and a new order of clinical transfusion proceedings management. The Portuguese Blood and Transplantation Institute with the other national responsible organizations formulated a normative contingency plan, in order to ensure and maintain a safe blood component support to all hospital requests. Regardless of the safety policies applied systematically in the transfusion process, such as routine nucleic acid tests in all donations, leukoreduction and pathogenic inactivation of blood components, the incomplete knowledge about the epidemiology and pathogenicity of SARS-CoV-2 suggests the precautionary principle. This lesson learned from previous outbreaks is a mandatory instruction in the transfusion medicine sector. Assuming the absence of vaccines and specific medication, reference laboratories of Blood and Transplantation Centers, Blood Functional Area, are intensively tagging the identification and screening of potential donors COVID-19 convalescent plasma as an alternative therapy.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-24
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25758/set.2265
oai:journals.ipl.pt:article/570
url https://doi.org/10.25758/set.2265
identifier_str_mv oai:journals.ipl.pt:article/570
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://journals.ipl.pt/stecnologia/article/view/570
https://doi.org/10.25758/set.2265
https://journals.ipl.pt/stecnologia/article/view/570/497
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2022 Saúde & Tecnologia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2022 Saúde & Tecnologia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Escola Superior de Tecnologia da Saúde de Lisboa (Instituto Politécnico de Lisboa)
publisher.none.fl_str_mv Escola Superior de Tecnologia da Saúde de Lisboa (Instituto Politécnico de Lisboa)
dc.source.none.fl_str_mv Saúde e Tecnologia; No. T3 (2020): Nº temático - COVID-19; e22-e28
Saúde & Tecnologia; N.º T3 (2020): Nº temático - COVID-19; e22-e28
1646-9704
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130660455055360